Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Inlyta
Pharma
Clearside's CLS-AX excels in phase 2b trial, set for phase 3
Clearside’s CLS-AX has aced a phase 2b trial, achieving primary and secondary outcomes for patients with neovascular age-related macular degeneration.
Kevin Dunleavy
Oct 9, 2024 11:47am
Lawmakers spotlight studies run at China military hospitals
Aug 20, 2024 2:34pm
ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC
May 23, 2024 5:00pm
Merck, Eisai turn up the heat in kidney cancer with survival win
Feb 13, 2021 12:39pm
BMS, Exelixis' Opdivo-Cabometyx continues kidney cancer streak
Feb 9, 2021 10:49am
Opdivo, Cabometyx in FDA fast lane for kidney nod
Oct 20, 2020 9:42am
